We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. (MRK) on Wednesday said the U.S. Food and Drug Administration approved a new monotherapy indication for its cancer drug Keytruda in a form of esophageal cancer.
The Kenilworth, N.J., drug maker said the approval covers patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (combined positive score >=10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, has previously been approved in indications in lung, skin, bladder and other cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 31, 2019 07:11 ET (11:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
